Causes and Consequences of Clonal Hematopoiesis with Unknown Drivers in 409,553 Whole-Genome Sequenced UK Biobank Participants
Sean Wen(Wellcome/MRC Cambridge Stem Cell Institute), Jonathan Mitchell(AstraZeneca (United Kingdom)), Andrew R. Harper(AstraZeneca (United Kingdom)), Margarete A. Fabre(University of Cambridge), Dimitrios Vitsios(AstraZeneca (United Kingdom)), Sebastian Wasilewski(AstraZeneca (United Kingdom)), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Slavé Petrovski(AstraZeneca (United Kingdom)), Marcin Karpiński(AstraZeneca (United Kingdom))
Cited by 3
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways
|Science|2015|980
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
|Cell Reports|2016|834
Clonal dynamics of haematopoiesis across the human lifespan
|Nature|2022|505